IBM's Confluent Bet Faces Earnings Test Amid Analyst Caution

IBM's Q1 2026 earnings, due April 22, will test its AI strategy and $11B Confluent deal. Despite a strong software backlog, analysts cut price targets citing macro headwinds.

Wall Street's mood has turned cautious on IBM as the tech giant prepares to report first-quarter earnings. The stock, trading around $242, has shed roughly 18% this year, reflecting investor unease. This skepticism persists despite a formidable $12.5 billion backlog in generative AI orders and a robust return on equity nearing 37%.

All eyes are on the upcoming earnings release scheduled for April 22, 2026, at 5:00 PM ET. The report will provide the first concrete data on the impact of IBM's recent $11 billion acquisition of data-streaming specialist Confluent. The deal, finalized in mid-March at $31 per share in cash—a 34% premium—is central to IBM's AI strategy, aiming to integrate Confluent with its watsonx.data platform. Over 6,500 companies, including 40% of the Fortune 500, already use Confluent's technology.

This strategic move, however, has been overshadowed by a wave of analyst target cuts. In a rare show of unanimity, three major firms recently lowered their price targets to an identical $290. Stifel and Needham both reduced their targets from $340, while BMO Capital trimmed its outlook from $350. The analysts cited a confluence of headwinds: geopolitical tensions, foreign exchange volatility from a strong dollar, and potential compression in software valuation multiples. Notably, all three firms maintained their positive or neutral ratings on the stock.

The software unit, which now accounts for approximately 45% of total revenue, is a critical growth engine. It grew 9% in 2025, marking IBM's highest annual software growth rate. For 2026, the company is targeting around 10% growth in this segment. The broader consulting backlog stands at $32 billion, with more than a quarter tied to generative AI projects.

For the upcoming quarterly results, Stifel anticipates a seasonally softer performance but expects constant-currency revenue growth between 4.5% and 5%. The firm models full-year earnings per share of $12.38. IBM's own guidance for 2026 calls for constant-currency revenue growth exceeding 5% and an increase in free cash flow to $15.7 billion.

Despite the lowered near-term targets, the average price objective among 13 analysts surveyed remains $311. This suggests a significant potential upside from the current share price, which trades well below its 200-day moving average. With a price-to-earnings ratio just under 22 and a PEG ratio of 0.3, the stock appears modestly valued within the sector. It also offers a dividend yield of about 2.7%, providing a defensive element often absent in pure-growth tech names.

The April 22 report will be a crucial indicator of whether IBM's fundamental strengths in software and AI can offset macroeconomic concerns and whether the hefty Confluent investment is beginning to pay off.